Cogent Biosciences, Inc. (COGT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cogent Biosciences, Inc. (COGT) trades at $39.56 with AI Score 60/100 (Grade B+). Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Market cap: $6.76B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026COGT stock analysis for 2026: Analysts have set a consensus price target of $49.75 for Cogent Biosciences, Inc., suggesting 25.8% upside from the current price of $39.56. The AI MoonshotScore is 60/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
COGT: 4/7 perspectives are bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Cogent Biosciences, Inc. (COGT) Healthcare & Pipeline Overview
Cogent Biosciences is a biotechnology firm specializing in precision therapies for genetically defined diseases, with a focus on its lead candidate, CGT9486, a selective tyrosine kinase inhibitor targeting KIT mutations. The company aims to address unmet needs in systemic mastocytosis and advanced gastrointestinal stromal tumors.
What Is the Investment Thesis for COGT?
Cogent Biosciences presents a compelling investment thesis centered on its precision medicine approach and the potential of CGT9486. The drug's selective targeting of the KIT D816V mutation in systemic mastocytosis offers a significant value driver, addressing a critical unmet need. Upcoming clinical trial results for CGT9486 will be a key catalyst, with positive data potentially leading to accelerated regulatory pathways. The company's licensing agreement with Plexxikon Inc. for bezuclastinib further strengthens its pipeline. However, potential risks include clinical trial setbacks, regulatory hurdles, and competition from existing and emerging therapies. The company's market capitalization of $6.76B reflects investor expectations for CGT9486's success. Continued progress in clinical development and strategic partnerships will be crucial for realizing the full potential of Cogent Biosciences.
Based on FMP financials and quantitative analysis
COGT Key Highlights
- Lead product candidate CGT9486 targets the KIT D816V mutation, a key driver in systemic mastocytosis.
- Licensing agreement with Plexxikon Inc. for bezuclastinib strengthens the company's pipeline.
- Market capitalization of $6.76B reflects investor confidence in the company's precision medicine approach.
- The company rebranded from Unum Therapeutics Inc. to Cogent Biosciences, Inc. in October 2020, signaling a strategic shift.
- Beta of 0.47 indicates lower volatility compared to the overall market.
Who Are COGT's Competitors?
COGT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| IBRX ImmunityBio, Inc. | $9.01 | -4.61% | $9.44B | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are COGT's Key Strengths?
- Focus on precision medicine and genetically defined diseases.
- Lead product candidate CGT9486 targets a specific genetic mutation.
- Licensing agreement with Plexxikon Inc. for bezuclastinib.
- Experienced management team with expertise in drug development.
What Are COGT's Weaknesses?
- Reliance on a limited number of product candidates.
- High risk associated with clinical development and regulatory approval.
- Competition from established pharmaceutical companies.
- Limited commercial infrastructure.
What Could Drive COGT Stock Higher?
- Clinical trial results for CGT9486 in systemic mastocytosis.
- Regulatory submissions for CGT9486.
- Expansion of CGT9486 into additional indications.
- Strategic partnerships and collaborations.
What Are the Key Risks for COGT?
- Negative return on equity (-83.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $366.6M recently.
- Clinical trial setbacks.
- Regulatory hurdles.
- Competition from existing and emerging therapies.
- Patent challenges.
- Reliance on key personnel.
What Are the Growth Opportunities for COGT?
- Expansion into Additional Indications: Cogent Biosciences has the opportunity to expand the application of CGT9486 beyond systemic mastocytosis and advanced GIST. Given its mechanism of action as a selective tyrosine kinase inhibitor, CGT9486 could potentially be effective in treating other diseases driven by KIT mutations. This expansion could significantly increase the addressable market and revenue potential. The timeline for exploring new indications depends on ongoing research and clinical trial results, but represents a long-term growth driver for the company. The market size for additional KIT-driven diseases could reach billions of dollars.
- Strategic Partnerships and Collaborations: Cogent Biosciences can pursue strategic partnerships and collaborations with other pharmaceutical and biotechnology companies to accelerate the development and commercialization of its therapies. Collaborations could provide access to new technologies, funding, and market expertise. The company's existing licensing agreement with Plexxikon Inc. demonstrates its ability to forge successful partnerships. The timeline for securing new partnerships is ongoing, with potential deals emerging as clinical programs advance. Strategic partnerships could unlock significant value and expand Cogent's reach.
- Advancements in Diagnostic Technologies: The increasing availability and sophistication of diagnostic technologies, such as genetic sequencing, are driving the adoption of precision medicine. As diagnostic tools become more accessible and affordable, more patients will be identified with genetically defined diseases that can be targeted by therapies like CGT9486. This trend will expand the market for Cogent Biosciences' products and services. The timeline for widespread adoption of advanced diagnostics is ongoing, with continuous improvements in technology and decreasing costs. This trend represents a long-term growth driver for the company.
- Regulatory Pathway Optimization: Cogent Biosciences can optimize its regulatory strategy to expedite the approval of its therapies. By leveraging accelerated approval pathways, such as breakthrough therapy designation and priority review, the company can potentially bring its products to market faster. A streamlined regulatory pathway can significantly reduce development costs and increase the return on investment. The timeline for regulatory approval depends on clinical trial results and interactions with regulatory agencies, but proactive engagement can improve the likelihood of success. Efficient regulatory strategies are crucial for maximizing the value of Cogent's pipeline.
- Commercialization and Market Access: Successful commercialization and market access are essential for realizing the full potential of Cogent Biosciences' therapies. The company needs to develop a robust commercial infrastructure and secure favorable reimbursement from payers. Effective marketing and sales strategies will be critical for driving adoption and generating revenue. The timeline for commercialization depends on regulatory approval and market readiness, but proactive planning can ensure a successful launch. Strong commercial execution is crucial for maximizing the financial returns from Cogent's innovative therapies.
What Opportunities Does COGT Have?
- Expansion into additional indications for CGT9486.
- Strategic partnerships and collaborations.
- Advancements in diagnostic technologies.
- Optimization of regulatory pathway.
What Threats Does COGT Face?
- Clinical trial setbacks.
- Regulatory hurdles.
- Competition from existing and emerging therapies.
- Patent challenges.
What Are COGT's Competitive Advantages?
- Proprietary technology targeting specific genetic mutations.
- Licensing agreements for key therapeutic candidates.
- Strong focus on precision medicine and genetically defined diseases.
What Does COGT Do?
Cogent Biosciences, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, is a biotechnology company dedicated to creating precision therapies for genetically defined diseases. Originally incorporated as Unum Therapeutics Inc., the company rebranded in October 2020 to reflect its refined strategic focus. Cogent's primary focus is on developing innovative treatments that target the underlying genetic drivers of diseases, with an initial emphasis on systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST). Their lead product candidate, CGT9486 (bezuclastinib), is a selective tyrosine kinase inhibitor specifically designed to inhibit the KIT D816V mutation, which is a primary driver of systemic mastocytosis. Additionally, CGT9486 targets other mutations in KIT exon 17, relevant in treating patients with advanced GIST. Cogent Biosciences operates under a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib, strengthening its position in the precision medicine landscape. The company's evolution from Unum Therapeutics to Cogent Biosciences signifies a strategic shift towards more targeted therapies and a commitment to addressing unmet medical needs in genetically defined diseases. Cogent's approach involves rigorous scientific research and clinical development to bring potentially transformative treatments to patients.
What Products and Services Does COGT Offer?
- Develop precision therapies for genetically defined diseases.
- Focus on treatments targeting specific genetic mutations.
- Lead product candidate is CGT9486, a selective tyrosine kinase inhibitor.
- Target the KIT D816V mutation in systemic mastocytosis.
- Address mutations in KIT exon 17 found in advanced gastrointestinal stromal tumors (GIST).
- Engage in research and clinical development to advance their pipeline.
- Collaborate with other companies through licensing agreements.
How Does COGT Make Money?
- Develop and commercialize precision therapies for genetically defined diseases.
- Focus on licensing agreements for research, development, and commercialization of therapies.
- Generate revenue through the sale of approved therapies.
What Industry Does COGT Operate In?
Cogent Biosciences operates within the biotechnology industry, which is characterized by rapid innovation, intense competition, and high regulatory scrutiny. The precision medicine segment, where Cogent focuses, is experiencing significant growth driven by advancements in genomics and targeted therapies. The competitive landscape includes companies developing similar kinase inhibitors and other targeted treatments for genetically defined diseases. Cogent's success depends on its ability to demonstrate clinical efficacy, navigate regulatory pathways, and secure market access for its therapies. The biotechnology industry is projected to continue growing, fueled by increasing demand for personalized medicine and innovative treatments.
Who Are COGT's Key Customers?
- Patients with systemic mastocytosis.
- Patients with advanced gastrointestinal stromal tumors (GIST).
- Healthcare providers who prescribe and administer the therapies.
ROE -83%Key Financial Metrics
Return on equity for Cogent Biosciences, Inc. stands at -83.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -39.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 15.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -16.7%, the inverse of the P/E and a quick read on earnings relative to price.
Cogent Biosciences, Inc. (COGT) Valuation Context
Valued at $6.76B, COGT is classified as a mid-cap stock. Relative to its peer group, COGT's quantitative score of 60/100 is below the peer average of 78/100.
Company Profile
Cogent Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Andrew R. Robbins. COGT has traded publicly since 2018.
F-Score 3/9Financial Health
Cogent Biosciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 11.23 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Cogent Biosciences, Inc. revenue of about $11.3M for fiscal 2026, with EPS near $-2.25. The estimate reflects 9 contributing analysts.
Net sellingInsider Activity
Over the past six months, Cogent Biosciences, Inc. insiders filed 13 SEC Form 4 transactions — 4 sales and 9 purchases. On net that is roughly 3.4M shares disposed (about $366.6M), a signal worth weighing alongside the fundamentals.
COGT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Cogent's recent insider buying suggests those in the know are confident in the company's future prospects. This can be a strong signal, like when insiders loaded up on Netflix before its streaming boom.
- The community buzz around Cogent is noticeably positive, with many seeing it as undervalued in the current market. This groundswell of support can drive momentum, similar to the early days of Tesla.
- Cogent's focus on precision oncology is gaining traction, aligning with a growing demand for targeted therapies. This positions them well for long-term growth, similar to how CRISPR companies benefited from gene editing advancements.
- Positive sentiment is building around potential partnerships and collaborations, which could significantly expand Cogent's reach and resources. This is akin to how smaller biotechs have thrived through strategic alliances with pharma giants.
Bear Case
- Recent market volatility is creating uncertainty for smaller biotech companies like Cogent. This mirrors the risk-off sentiment during the 2008 financial crisis, impacting even promising firms.
- Despite positive sentiment, some community members express concerns about the competitive landscape in oncology. This echoes the challenges faced by companies entering crowded markets, like the early days of the electric vehicle sector.
- There are lingering questions about the long-term efficacy and safety of Cogent's lead drug candidate. This is a common concern in drug development, similar to the scrutiny faced by novel therapies in their early stages.
- Some investors are worried about potential delays in clinical trials or regulatory approvals, which could push back timelines and impact investor confidence. This is a constant risk in the biotech industry, reminiscent of the setbacks faced by many companies during the COVID-19 vaccine race.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
COGT Latest News
-
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage
seekingalpha.com · Jun 14, 2026
-
Sector Update: Healthcare Stocks Softer in Afternoon Trading
MT Newswires · Jun 12, 2026
-
Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial
Yahoo! Finance: COGT News · Jun 12, 2026
-
Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor At The 2026 European Hematology Association Congress, June 11-14
benzinga · Jun 12, 2026
COGT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for COGT.
Price Targets
Consensus target: $49.75
COGT MoonshotScore
What does this score mean?
The MoonshotScore rates COGT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage
Sector Update: Healthcare Stocks Softer in Afternoon Trading
Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial
Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor At The 2026 European Hematology Association Congress, June 11-14
Latest Cogent Biosciences, Inc. Analysis
Leadership: Andrew R. Robbins
CEO
Andrew R. Robbins serves as the Chief Executive Officer of Cogent Biosciences, Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. Prior to joining Cogent, Robbins held leadership positions at various companies, contributing to strategic planning, business development, and commercialization efforts. His expertise spans across multiple therapeutic areas, with a focus on oncology and precision medicine. Robbins' experience positions him to lead Cogent Biosciences in its mission to develop innovative therapies for genetically defined diseases.
Track Record: Under Andrew R. Robbins' leadership, Cogent Biosciences has focused on advancing the clinical development of CGT9486 and expanding its pipeline. He has overseen the company's strategic shift towards precision medicine and the rebranding from Unum Therapeutics. Robbins has also been instrumental in securing partnerships and collaborations to support the company's growth. His leadership has been focused on driving innovation and creating value for shareholders.
Cogent Biosciences, Inc. Healthcare Stock: Key Questions Answered
What does Cogent Biosciences, Inc. do?
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Their primary focus is on creating innovative treatments that target the underlying genetic drivers of diseases, with an initial emphasis on systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST). Their lead product candidate, CGT9486, is a selective tyrosine kinase inhibitor specifically designed to inhibit the KIT D816V mutation, which is a primary driver of systemic mastocytosis, as well as other mutations in KIT exon 17, relevant in treating patients with advanced GIST.
What do analysts say about COGT stock?
Analyst coverage of Cogent Biosciences, Inc. (COGT) typically focuses on the clinical development progress of CGT9486 and its potential market opportunity. Key valuation metrics include price targets based on future revenue projections and discounted cash flow analysis. Growth considerations revolve around the successful completion of clinical trials, regulatory approvals, and commercial launch of CGT9486. Analyst consensus generally reflects optimism regarding the company's precision medicine approach and the unmet need in systemic mastocytosis and advanced GIST. However, potential risks such as clinical trial setbacks and regulatory hurdles are also considered.
What are the main risks for COGT?
The main risks for Cogent Biosciences, Inc. include the inherent uncertainties associated with clinical development, such as the possibility of clinical trial setbacks or failure to demonstrate efficacy. Regulatory hurdles, including potential delays or rejection of regulatory submissions, also pose a significant risk. Competition from existing and emerging therapies in the systemic mastocytosis and GIST markets could impact the company's market share and revenue potential. Additionally, patent challenges and intellectual property disputes could threaten the company's proprietary technology and market exclusivity.
What are the key factors to evaluate for COGT?
Cogent Biosciences, Inc. (COGT) holds an AI score of 60/100 (moderate). Analysts target $49.75 (+26%). Not financial advice.
How frequently does COGT data refresh on this page?
COGT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven COGT's recent stock price performance?
Cogent Biosciences, Inc. (COGT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on precision medicine and genetically defined diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider COGT overvalued or undervalued right now?
Valuing Cogent Biosciences, Inc. (COGT) requires multiple metrics. Analysts target $49.75 (+26%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying COGT?
Before investing in Cogent Biosciences, Inc. (COGT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- Investment decisions should be based on thorough research and consultation with a financial advisor.